New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
06:07 EDTIMGNImmunoGen downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded ImmunoGen citing valuation and keeps a $14 price target for shares. The firm believes success of T-DM1 is now fully priced into shares.
News For IMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 3, 2015
10:00 EDTIMGNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:44 EDTIMGNImmunoGen downgraded to Hold from Buy at Cantor
Cantor Fitzgerald analyst Mara Goldstein downgraded ImmunoGen to Hold citing the recent really in shares. The analyst raised her price target for the stock to $21 from $12.
July 31, 2015
06:36 EDTIMGNImmunoGen: enrollment in expansion cohort for IMGN853 to complete by year end
Subscribe for More Information
06:34 EDTIMGNImmunoGen sees FY16 revenue $70M-$80M, consensus $87.4M
Sees FY16 operating expenses $175M-$180. Sees FY16 net loss to be 120M-$125M. Sees FY16 cash used in operations $100M-$105M. Sees FY16 CapEx $13M-$15M. Sees FY16 cash and marketable securities anticipated to be $165M-$170M.
06:32 EDTIMGNImmunoGen reports Q4 EPS (35c), consensus (35c)
Reports Q4 revenue $12.61M, consensus $15.42.
July 29, 2015
08:29 EDTIMGNImmunoGen price target raised to $24 from $13 at Oppenheimer
Oppenheimer hiked its price target on ImmunoGen as the firm thinks that updates on its '853 drug will better frame the drug's value. The firm believes that several other positive catalysts will propel the stock higher in 2016. It keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use